Hematology and Oncology

EmailEmail    |   Bookmark Page Bookmark  |   RSS Feeds RSS  |   Print Page Print  

Mehdi Hamadani, M.D.

Associate Professor of Medicine

Mehdi Hamadani, M.D., is Associate Professor of Medicine at the Medical College of Wisconsin, Division of Hematology and Oncology, specializing in lymphoma, multiple myeloma and bone marrow transplantation.  He graduated from King Edward Medical College (with honors) in Pakistan in 2001, he then completed his internal medicine residency at Oklahoma University Health Sciences Center in Oklahoma City, Oklahoma, and a Fellowship in Hematology and Oncology at The Ohio State University. He received the James V. Warren Award for Accomplishments as The Most Outstanding Research Fellow, during his fellowship. Dr. Hamadani served as an Associate Professor of Medicine and Director of Myeloma & Lymphoma Program at West Virginia University before joining MCW. He has authored nearly 80 peer-reviewed publications, and has been invited as a speaker for several national and international meetings. He is the recipient of Conquer Cancer Foundation of ASCO Career Development Award and ASBMT New Investigator Award.  During his tenure at West Virginia University, Dr. Hamadani also received Best Attending Physician, Outstanding Teacher, and several Press Ganey Top Provider Awards. His clinical research focuses on lymphoid malignancies and hematopoietic cell transplantation.  Dr. Hamadani is board certified in Internal Medicine, Hematology and Medical Oncology.

Publications

  1. Hamadani M., Kharfan-Dabaja M., Kamble R., Awab A., William K., Ozer H.: “Primary Malignant Lymphoma of the Uterus. An Extranodal Lymphoma with an Ominous Five Year Survival.” Pakistan Journal of Radiology. 2004 October-December;15(4):11-17.

  2. Hamadani M., Tfayli A., Sethi S., Awab A., Hamdani N.:Granulocytic sarcoma manifesting as multiple skeletal lesions.” Am J Med Sci. 2005 September;330(3):139-143.

  3. Kamble RT., Hamadani M., Selby GB.: “Increased mean corpuscular volume after autologous hematopoietic stem cell transplantation: incidence and significance.” Biol Blood Marrow Transplant. 2006 January;12(1):111-112.

  4. Kamble RT., Hamadani M., Selby GB.: “Delayed myeloid engraftment due to vancomycin in allogeneic haematopoietic stem cell transplant recipients.” J Antimicrob Chemother. 2006 April; 57(4):795-796. Epub 2006 Feb 13.

  5. Hamadani M., Kharfan-Dabaja M., Kamble R., Kern W., Ozer H.:Marginal zone B-cell lymphoma of the uterus: a case report and review of the literature.” J Okla State Med Assoc. 2006 April;99(4):154-156.

  6. Hamadani M., Awab A., Rashid A., Ali T., Brown B.: “Fibrous dysplasia protuberans in a patient with McCune-Albright syndrome.” J Coll Physicians Surg Pak. 2006 May;16(5):376-377.

  7. Hamadani M., Awab A., Chaudhary L., Tfayli A.: “Relative efficacy of ondansetron, granisetron, dolasetron and palonosetron in controlling acute nausea and vomiting associated with platinum-based chemotherapy.” J Oncol Pharm Pract. 2006 June;12(2):67-68.

  8. Awab A., Hamadani M., Sud B., Voskuhl GW.: “Infected atrial myxoma.” Med J Aust. 2006 September;185(6):332.

  9. Awab A., Hamadani M., Saya S., Whitsett T.: “Early detection of digitalis-induced nonocclusive mesenteric ischemia using Doppler ultrasonography.” South Med J. 2006 October;99(10):1142.

  10. Hamadani M., Awan F.: “Role of thiamine in managing ifosfamide-induced encephalopathy.” J Oncol Pharm Pract. 2006 December;12(4):237-239.

  11. Hamadani M., Chaudhary AL.: “McCune-Albright Syndrome.” Med J Aust. 2006 December;185(11-12):597.

  12. Tfayli A., Selby G., Maqbool F., Bierbaum W., Hamadani M.: “Role of intra-arterial steroid administration in the management of steroid-refractory acute gastrointestinal graft-versus-host disease.” Am J Hematol. 2006 December;81(12):959-962.

  13. Hamadani M., Martin LK, Benson DM., Copelan EA., Devine SM., Hofmeister CC.: “Central nervous system post-transplant lymphoproliferative disorder post allograft despite negative serum and spinal fluid Epstein-Barr virus DNA PCR.” Bone Marrow Transplant. 2007 February;39(4):249-251.

  14. Ali T., Hasan M., Hamadani M., Harty RF.: “Gastroparesis.” South Med J. 2007 March;100(3):281-286.

  15. Awan F., Hamadani M.: “Gastrointestinal chronic graft-versus-host disease: management Options.” J Oncol Pharm Pract. 2007 March;13(1):49-51.

  1. Hamadani M., Benson DM Jr., Copelan EA.: “Thalidomide-induced fulminant hepatic failure.” Mayo Clin Proc. 2007 May;82(5):638.

  1. Hamadani M., Chaudhary L., Awan FT., Khan JK., Kojouri K., Ozer H., Tfayli A.: “Management of platinum-based chemotherapy-induced acute nausea and vomiting. Is there a superior serotonin receptor antagonist?” J Oncol Pharm Pract. 2007 June;13(2):69-75.

  1. Awan F., Hamadani M., Devine S.: “Paraneoplastic Sweet's syndrome and the pathergy phenomenon.” Ann Hematol. 2007 Aug:86(8):613-614. Epub 2007 April 28.

  2. Awab A., Hamadani M., Peyton M., Brown B.: "False negative PET-scan with bronchioloalveolar carcinoma: an important diagnostic caveat." Am J Med Sci. 2007 October; 334(4):311-313.

  3. Vrindavanam N., Hamadani M., Steele B., Awan F., Suster S., Benson DM Jr. “Dramatic response to single-agent rituximab in a patient with intravascular lymphoma.” Am J Hematol. 2007 December;82(12):1120-1121. Epub 2007 July 25.

  4. Hamadani M., Magro CM., Porcu P.: “CD4+ CD56+ haematodermic tumour (plasmacytoid dendritic cell neoplasm).” Br J Haematol. 2008 January;140(2):122. Epub 2007 November 7.

  1. Hamadani M., Benson DM Jr., Blum W., Garzon R., Devine SM.: “Pulmonary nocardia and aspergillus co-infection in a patient with chronic graft-versus-host disease.” Transpl Infect Dis. 2008 February;10(1):24-26. Epub 2007 July 25.

  1. Hamadani M., Hade E., Benson DM Jr., Hofmeister CC.: “The effect of statin use at the time of autologous transplant on response and survival in multiple myeloma.” Biol Blood Marrow Transplant. 2008 March;14(3):351-352.

  1. Hamadani M., Awan FT., Elder P., Lin TS., Porcu P., Blum KA., Devine SM.: “Allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphomas; evidence of graft-versus-T-cell lymphoma effect.” Biol Blood Marrow Transplant. 2008 April;14(4):480-483.

  1. Hamadani M., Awan F., Villalona-Calero MA.:  “Malignant thymoma with immunodeficiency (Good syndrome) associated with Mucormycosis.” Am J Clin Oncol. 2010 February;33(1):109.

  1. Hamadani M., Awan FT., Devine SM.: “The impact of HMG-CoA reductase inhibition on the incidence and severity of graft-versus-host disease in patients with acute leukemia undergoing allogeneic transplantation.” Blood. 2008 April;111(7):3901-3902.

  1. Hamadani M., Awan FT., Copelan EA.: “Hematopoietic stem-cell transplantation in adults with acute myeloid leukemia.” Biol Blood Marrow Transplant. 2008 May;14(5):556-567.

  2. Hamadani M., Hofmeister CC., Jansak B., Phillips G., Elder P., Blum W., Penza P., Lin TS., Klisovic R., Marcucci G., Farag SS., Devine SM.: “Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation.” Biol Blood Marrow Transplant. 2008 July;14(7):783-789.

  3. Hamadani M., Awan FT., Elder P., Lin TS., Porcu P., Benson DM Jr., Blum KA., Devine SM.: "Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma." Leuk Lymphoma. 2008 October;49(10):1893-1898.

  4. Ferreri AJ., Dognini GP., Govi S., Bouzani M., Bollinguer CR., D'Incan M., Delaporte E., Hamadani M., Jardin F., Martusewicz-Boros F., Montanari M., Szomor A., Crocchiolo R., Zucca E., Cavalli C., Ponzoni M.: “Can rituximab change the usually dismal prognosis of patients with intravascular large B-cell lymphoma?” J Clin Oncol. 2008 November;26(31):5134-5136. Epub 2008 October 6.

  1. Hamadani M., Benson DM Jr., Lin TS., Porcu P., Blum KA., Devine SM.: “High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma.” Eur J Haematol. 2008 December;81(6):425-431. Epub 2008 September 4.

  1. Blum KA., Hamadani M., Phillips GS., Lozanski G., Johnson AJ., Lucas DM., Smith LL., Baiocchi R., Lin TS., Porcu P., Devine SM., Byrd JC.: “Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin’s lymphoma.” Leuk Lymphoma. 2009 March;50(3):349-356. Epub 2009 March 4.

  1. Hamadani M., Benson DM Jr., Hofmeister CC., Elder P., Blum W., Porcu P., Garzon R., Blum KA., Lin TS., Marcucci G., Devine SM.: “Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-Hodgkin's lymphomas.” Biol Blood Marrow Transplant. 2009 May;15(5):547-553. Epub 2009 March 9.

  1. Hamadani M., Devine SM.: “Reduced intensity conditioning allogeneic stem cell transplantation in HIV patients with hematological malignancies: yes we can.” Blood. 2009 September;114(12):2564-2566.

  1. Hamadani M., Blum W., Phillips G., Elder P., Andritsos L., Hofmeister C., O’Donnell L., Klisovic R., Penza S., Garzon R., Krugh D., Lin T., Bechtel T., Benson DM., Byrd JC., Marcucci G., Devine SM.: “Improved non-relapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced intensity conditioning allogeneic transplantation for hematologic malignancies.” Biol Blood Marrow Transplant. 2009 November;15(11):1422-1430.

  1. Pant S., Hamadani M., Dodds AJ., Szer J., Crilley PA., Stevenson D., Phillips G., Elder P, Nivison-Smith I, Avalos BR., Penza S., Topolsky D., Sobecks R., Kalaycio M., Bolwell BJ., Copelan EA.: “Incidence and reasons for late failure after allogeneic hematopoietic cell transplantation following BuCy2 in acute myeloid leukemia.” Br J Haematol. 2010 February;148(4):623-626.

  1. Benson DM Jr., Panzner K.,  Hamadani M., Hofmeister CC., Bakan CE., Smith MK., Elder P., Krugh D., O’Donnell L., and Devine SM.: “Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma.” Leuk Lymphoma. 2010 Februrary;51(2):243-251.

  1. Hamadani M., Awan FT.: "Remission induction, consolidation and novel agents in development for adults with acute myeloid leukemia." Hematol Oncol. 2010 March;28(1):3-12.

  1. Christian B., Zhao W., Hamadani M., Sotomayor, EM., Narvarro W., Devine SM., Racke F., Blum KA.: “Mantle cell lymphoma twelve years after allogeneic bone marrow transplant occurring simultaneously in recipient and donor.” J Clin Oncol. 2010 November;28(31):e629-632. Epub 2010 Aug 23.

  1. Hamadani M., Craig M., Awan FT., Devine SM.: “How we approach patient evaluation for hematopoietic stem cell transplantation.” Bone Marrow Transplant. 2010 August;45(8):1259-1268. Epub 2010 May 17.

  1. Awan FT., Osman S., Kochuparambil ST., Gibson L., Remick SC., Abraham J., Craig M., Jillella A., Hamadani M.: “Impact of response to thalidomide, lenalidomide or bortezomib containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation.” Bone Marrow Transplant. 2012 January;47(1):146-148. Epub 2011 Feb 28.

  1. Hamadani M., Craig M., Phillips G., Abraham J., Tse W., Cumpston C., Gibson L., Remick S., Hofmeister C., Penza S., Efebera Y., Andritsos L., Garzon R., Benson D., Blum W., Devine SM.: “Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic hematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning.” Hematol Oncol. 2011 December;29(4):202-210. Epub 2011 Feb 28.

  1. Hamadani M., Craig M., Gibson L., Remick S.: “The evolving role of statins in hematopoietic stem and progenitor cell transplantation.” Am J Blood Res. 2011 June;1(1):57-64.

  1. Kumar S., Zhang M., Li P., Dispenzieri A., Milone G., Lonial S., Krishnan A., Maiolino A., Wirk B., Weiss B., Freytes C., Vogl D., Vesole D., Lazarus H., Meehan K., Hamadani M., Lill M., Callander N., Majhail N., Wiernik P., Nath R., Kamble R., Vij R., Kyle R., Gale R., Hari P.: “Trends in allogeneic stem cell transplantation for multiple myeloma: a center for international blood and marrow transplant research (CIBMTR) analysis.” Blood. 2011 Aug;118(7)1979-1988. Epub 2011 Jun 20.

  1. Liu K., Anthony BA., Liu K., Yearsly MM., Hamadani M., Devine SM., Hadley GA.: “CD103 deficiency prevents graft-versus-host disease but spares graft-versus-tumor effects mediated by alloreactive CD8 T cells.” PLoS One. 2011;6(7): e21968. Epub 2011 Jul 14.

  1. Kanate AS., Craig M., Cumpston A., Saad A., Hobbs G., Leadmon S., Bunner P., Watkins K., Bulian D., Gibson L., Abraham J., Remick SC., Hamadani M.: “Higher infused CD34+ cell dose and overall survival in patients undergoing in vivo T-cell depleted, but not T-cell replete allogeneic peripheral blood hematopoietic cell transplantation.” Hematol Oncol Stem Cell Ther. 2011;4(4):149-156.

  1. Hamadani M., Kochuparambil ST., Osman S., Cumpston A., Leadmon S., Bunner P., Watkins K., Morrison D., Speir E., DeRemer D., Kota V., Jillella A., Craig M., Awan F.: “Intermediate- versus low-dose cyclophosphamide and granulocyte colony stimulating factor for peripheral blood stem cell mobilization in multiple myeloma patients treated with novel induction therapies.” Biol Blood Marrow Transplant. 2012 Jul;18(7):1128-1135. Epub 2012 Jan 13.

  1. Sweet M., Cumpston C., Briggs F., Craig M., Hamadani M.: “Impact of alcohol impregnated port protectors and needleless neutral pressure connectors on central line-associated  blood stream infections and contamination of blood cultures in an inpatient hematology and oncology unit.” Am J Infect Control. 2012 Dec;40(10):931-934. Epub 2012 May 8.

  1. Awan F., Kochuparambil ST., DeRemer D., Cumpston A., Craig M., Jillella A., Hamadani M.: "Plerixafor salvage is safe and effective in hard-to-mobilize patients undergoing chemotherapy and filgrastim-based peripheral blood progenitor cell mobilization." J Oncol. 2012;2012: 931071. Epub 2012 Apr 10.

  1. Ranganathan P., Heaphy C., Costinean S., Stauffer N., Na C., Hamadani M., Santhanam R., Mao C., Taylor P., Sandhu S., He G., Shana'ah A., Nuovo G., Obad S., Broom O., Kauppinen S., Byrd JC., Caligiuri M., Perotti D., Hadley G., Marcucci G., Devine SM., Blazar B., Croce C., Garzon R.: “Regulation of acute graft-versus-host disease by microRNA-155.” Blood. 2012 May;119(20)4786-4797. Epub 2012 Mar 9.

  1. Ballen KK., Woolfrey A., Zhu X, Ahn K., Wirk B., Arora M., George B., Savani B., Bolwell B., Porter D., Copelan E., Hale G., Schouten H., Lewis I., Cahn J., Halter J., Cortes J., Kalaycio M., Antin J., Aljurf M., Carabasi M., Hamadani M., McCarthy P., Pavletic S., Gupta V., Deeg H., Maziarz R., Horowitz M., Saber W.: “Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia.” Biol Blood Marrow Transplant. 2012 Sep;18(9):1446-1454. Epub 2012 Mar 23.

  1. Ross A., Slain D., Cumpston A., Bryant AM., Hamadani M., Craig M.: “An evaluation of an alternative posaconazole prophylaxis regimen in hematologic malignancy patients receiving concomitant stress ulcer prophylaxis.” Int J Antimicrob Agents. 2012 Dec;40(6):557–561. Epub 2012 Oct 12.

  1. Cumpston A., Craig M., Hamadani M., Abraham J., Hobbs GR., Sarwari AR.: “Extended follow-up of an antibiotic cycling program for the management of febrile neutropenia in a hematologic malignancy and hematopoietic cell transplantation unit.” Transpl Infect Dis. 2013 Apr;15(2):142-149. Epub 2012 Dec 20.

  1. Palla A., Hamadani M.: “Rituximab maintenance versus retreatment in follicular lymphoma.” Hematol Oncol. Epub 2012 Oct 9.

  1. Kanate AS., Kharfan-Dabaja M., Hamadani M.: “Controversies and recent advances in hematopoietic cell transplantation for follicular non-Hodgkin lymphoma.” Bone Marrow Res. 2012;2012:897215. Epub 2012 Oct 11.

  1. Maramattom L., Hari P., Burns L., Carreras J., Arcese W., Cairo M., Costa L., Fenske T., Lill M., Freytes C., Gale R., Gross T., Hale G., Hamadani M., Holmberg L., Hsu J., Inwards D., Lazarus H., Marks D., Maloney D., Maziarz R., Montoto S., Rizzieri D., Wirk B., Gajewski J.: “Autologous and allogeneic transplantation for Burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research.” Biol Blood Marrow Transplant.  2013 Feb;19(2):173-179. Epub 2012 Nov 29.

  1. Kharfan-Dabaja MA., Hamadani M., Reljic T., Nishihori T., Bensinger W., Djulbegovic B., Kumar A.: “Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials.” J Hematol Oncol. 2013:6;2. Epub 2013 Jan 4.

  1. Hamadani M., Saber W., Ahn W., Carreras J., Cairo M., Fenske T., Gale R., Gibson J., Hale G., Hari P., Hsu J., Inwards D., Kamble R., Klein A., Maharaj D., Marks D., Rizzieri D., Savani B., Schouten H., Waller E., Wirk B., Lazarus HM.: “Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: A short analysis from the CIBMTR.” Biol Blood Marrow Transplant. 2013 Apr;19(4):625-631. Epub 2013 Jan 17.

  1. Hamadani M., Saber W., Ahn W., Carreras J., Cairo M., Fenske T., Gale R., Gibson J., Hale G., Hari P., Hsu J., Inwards D., Kamble R., Klein A., Maharaj D., Marks D., Rizzieri D., Savani B., Schouten H., Waller E., Wirk B., Laport G., Montoto S., Maloney D., Lazarus HM.: “Impact of pretransplant conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B-cell lymphoma and grade-III follicular lymphoma”. Biol Blood Marrow Transplant. 2013 May;19(5):746-753. Epub 2013 Feb 1.

  1. Kharfan-Dabaja MA., Lazarus HM., Nishihori T., Mahfouz RA., Hamadani M.: “Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: a focus on hematopoietic cell transplantation.” Biol Blood Marrow Transplant. 2013 Jul;19(7):1006-1012. Epub 2013 Feb 5.

  1. Awan F.,  Kochuparambil ST., Falconer DE., Cumpston C., Leadmon S., Watkins K., DeRemer D., Jillella A., Craig M., Hamadani M.: “Comparable efficacy and lower cost of peripheral blood stem cell mobilization with intermediate-dose cyclophosphamide and G-CSF compared to plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies.” Bone Marrow Transplant. 2013 Oct;48(10) 1279-1284. Epub 2013 Apr 15.

  1. Chaudhary L., Kharfan-Dabaja MA., Hari P., Hamadani M.: “Is hematopoietic cell transplantation still a valid option for mantle cell lymphoma in first remission in the chemoimmunotherapy-era?” Bone Marrow Transplant. Epub 2013 Apr 15.

  1. Veltri L., Regier M., Cumpston A., Leadmon S., Tse W., Craig M., Hamadani M.: “Incidence and pattern of graft-versus-host disease in patients undergoing allogeneic transplantation after non-myeloablative conditioning with total lymphoid irradiation and antithymocyte globulin.” Bone Marrow Res. 2013;2013:414959. Epub 2013 Apr 17.

  1. Kharfan-Dabaja MA., Nishihori1 T., Otrock ZK., Haidar H., Mohty M., Hamadani M.: “Monoclonal antibodies in conditioning regimens for hematopoietic cell transplantation.” Biol Blood Marrow Transplant. 2013 Sep;19(9):1288-300. Epub 2013 Apr 22.

  1. Chaudhary L., Awan F., Cumpston A., Leadmon S., Watkins K.., Tse W., Craig M., Hamadani M.: “Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.” J Clin Apher. 2013 Oct;28(5):359-367. Epub 2013 Jun 14.

  1. Kanate A., Watkins K., Cumpston A., Craig M. Hamadani M.: “Salvage bone marrow harvest in patients failing plerixafor-based stem cell mobilization attempt: Feasibility and autologous transplantation outcomes.” Biol Blood Marrow Transplant. 2013 Jul;19(7):1133-1135. Epub 2013 Apr 28.

  1. Kharfan-Dabaja MA.,* Hamadani M.,* Reljic T., Pyngolil, P., Komrokji R., Lancet J., Fernandez HF., Djulbegovic B., Kumar A.: “Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukemia: a systematic review and meta-analysis.” Br J Haematol. 2013 Nov;163(3):315-325. Epub 2013 Aug 23. [*Authors contributed equally]

  1. Hamadani M., Gibson LF., Remick SC., Wen S., Petros W., Tse W., Brundage KM., Vos J., Cumpston A., Bunner P., Craig MD.: “Sibling donor and recipient immune modulation with atorvastatin for the prophylaxis of acute graft-versus-host disease.” J Clin Oncol. Epub 2013 Oct 28.

  1. Fenske T., Zhang M., Carreras J., Ayala E., Burns L., Cashen A., Costa L., Freytes C., Gale R., Hamadani M., Holmberg L., Inwards D., Lazarus H., Maziarz R., Munker R., Perales M., Rizzieri R., Schouten H., Smith S., Waller E., Wirk B., Laport G., Maloney D., Montoto S., Hari P.: “Autologous or reduced-intensity allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle cell lymphoma: analysis of transplant timing and modality.” J Clin Oncol. In Press.

  1. Truong Q., Shah N., Knestrick M., Curley B., Hu Y., Craig M., Hamadani M.: “Limited utility of surveillance imaging for detecting disease relapse in non-Hodgkin lymphoma patients in first complete remission.” Clin Lymphoma Myeloma Leuk . Epub 2013 Oct 10.

  1. Copelan E., Hamilton B., Avalos B., Ahn K., Bolwell B., Zhu X., Aljurf M., van Besien K., Bredeson C., Cahn J., Costa J., deLima M., Gale R., Hale G., Halter J., Hamadani M., Inamoto Y., Kamble R., Litzow M., Loren A., Marks D., Olavarria E., Roy V., Sabloff M., Savani B., Seftel M., Schouten H., Ustun C., Waller E., Weisdorf D., Wirk B., Horowitz M., Arora M., Szer, J. Cortes J., Kalaycio M., Maziarz R., Saber W.: “Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared to TBI.” Blood. Epub 2013 Sep 24.

  1. Truong Q., Veltri L., Kanate AS., Hu Y., Craig M., Hamadani M., Cumpston A.: “Impact of the duration of antiviral prophylaxis on rates of varicella zoster virus reactivation disease in autologous hematopoietic cell transplantation recipients.” Ann Hematol. Epub 2013 Oct 6.

  1. Gupta V., Malone A., Hari P., Ahn K., Hu Z., Gale R., Ballen K., Hamadani M., Olavarria E., Gerds A., Waller E., Costa L., Antin J., Kamble R., van Besien K., Savani B., Schouten H., Szer J., Cahn J., de Lima M., Wirk B., Aljurf M., Popat U., Bejanyan N., Litzow M., Norkin M., Lewis I., Hale G., Woolfrey A., Miller A., Ustun C., Jagasia M., Lill M., Maziarz R., Cortes J., Kalaycio M., Saber W.: “Reduced intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research.” Biol Blood Marrow Transplant. Epub 2013 Oct 23.

 

Invited Reviews And Commentaries

  1. Hamadani SM., Chaudhary L.: “Limitations of Sokal score in patients with chronic myeloid leukemia.” J Coll Physicians Surg Pak. 2007 Mar;17(3):182.

  2. Hamadani M., Kraut EH.: “Isolated skeletal involvement in hairy cell leukemia.” Clin Adv Hematol Oncol. 2008 April;6(4):294-296.

  3. Hamadani M., Blum W.: “Role of hematopoietic stem cell transplantation in adults with acute myeloid leukemia.” Clinical Leukemia. 2009 February;3(1):47-57.

  4. Hamadani M., Mohty M., Kharfan-Dabaja MA.: “Reduced-intensity conditioning allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia.” Cancer Control. 2011 October;18(4):237-245.

  5. Hamadani M.: “Reappraising the role of autologous transplantation for indolent B-cell lymphomas in the chemoimmunotherapy era: is it still relevant?” Bone Marrow Transplant. 2013 August;48(8):1013-1021. Epub 2012 Sep 24.

  6. Chaudhary L., Hamadani M.: “Management strategies for follicular lymphoma patients in remission after modern frontline chemoimmunotherapies.” J Blood Disorders Transf. 2013 January;4(1): 1000e105.

  7. Hamadani M., Kanate AS.: “Dawn of a new era: targeting the B-cell receptor signaling pathway to conquer B-cell lymphomas.” Community Oncology. 2013 October;10(10):279-281.

 

 

webmaster@mcw.edu
© 2014 Medical College of Wisconsin
Page Updated 10/15/2014